Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Dec 04, 2019 02:53 PM IST | Source: PTI

Shilpa Medicare gets EIR from USFDA for Raichur facility

An EIR is given to a unit on successful closure of an inspection conducted by the United States Food and Drug Administration (USFDA).

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Pharma firm Shilpa Medicare on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Raichur facility in Karnataka.

An EIR is given to a unit on successful closure of an inspection conducted by the United States Food and Drug Administration (USFDA).

The company announced successful closure of the inspection conducted at its active pharmaceutical ingredient (API) manufacturing site at Raichur with the receipt of EIR from the USFDA, Shilpa Medicare said in a filing to the BSE.

Close

The inspection was conducted from July 22-26, 2019 , it added.

Shilpa Medicare stock was trading at Rs 292, up 0.69 per cent from the previous close, on the BSE.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Dec 4, 2019 02:48 pm
Sections
Follow us on
Available On